자궁경부암 치료 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 치료법별, 최종 용도별, 지역별 및 부문별 전망(2026-2033년)

The global cervical cancer treatment market size was valued at USD 9.1 billion in 2025 and is projected to grow from USD 9.6 billion in 2026 to USD 14.0 billion in 2033, at a CAGR of 5.6% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 40.0% in 2025. This growth is attributed to advancements in oncology technology, the rising incidence of cervical cancer, recent innovations in imaging devices by leading market players, and a general rise in women's health consciousness and lifestyle changes.

Women living with HIV are significantly more vulnerable to cervical cancer, illustrating the intersection of health disparities and cancer risk. The global increase in cervical cancer cases is largely influenced by access to HPV vaccination, screening, and treatment, especially in low- and middle-income countries where the burden is the greatest. Socioeconomic factors, such as poverty and gender bias, further exacerbate these inequities.

According to the World Health Organization's 2025 Cervical Cancer Fact Sheet, cervical cancer remains the fourth most common cancer among women worldwide, with an estimated 660,000 new cases. Approximately 94% of cervical cancer deaths occur in low- and middle-income countries, highlighting the persistent disparities in access to HPV vaccination, screening, and treatment services. This underscores the urgent need for enhanced cervical cancer diagnosis and treatment globally. Sub-Saharan Africa, Southeast Asia, and Central America exhibit the highest rates of cervical cancer. The leading cause of this disease is the Human Papillomavirus (HPV), which is responsible for 95% of cervical cancer deaths. These statistics emphasize the seriousness of the cervical cancer issue and call for global attention to develop solutions and create opportunities for market growth.

In addition, in 2024, the Indian government announced the 'NARI SHAKTI' scheme, providing vaccination for girls aged 9 to 14 to prevent cervical cancer. Initiatives from the UN, WHO, and other major governmental organizations are paving the way for industry players to expand their market share and significantly grow the market.

Global Cervical Cancer Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cervical cancer treatment market report based on type, treatment, end use, and region:

• Type Outlook (Revenue, USD Billion, 2021 - 2033)

Squamous Cell Carcinoma

Adenocarcinoma

Adenosquamous Carcinoma

Other Types

• Treatment Outlook (Revenue, USD Billion, 2021 - 2033)

Radiation Therapy

• External Beam Radiation Therapy (EBRT)
• Brachytherapy

Chemotherapy

• Cisplatin
• Carboplatin
• Paclitaxel
• Other Chemotherapeutic Agents

Targeted Therapy

• Bevacizumab (Avastin)
• Other Targeted Therapies

Immunotherapy

• Pembrolizumab (Keytruda)
• Other Immune Checkpoint Inhibitors

Other Therapies

• End Use Outlook (Revenue, USD Billion, 2021 - 2033)

Hospitals & Clinics

Ambulatory Surgery Centers

Others

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

North America

• U.S.
• Canada
• Mexico

Europe

• Germany
• UK
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway

Asia Pacific

• China
• Japan
• India
• South Korea
• Australia
• Thailand

Latin America

• Brazil
• Argentina

Middle East and Africa (MEA)

• Saudi Arabia
• UAE
• South Africa
• Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Cervical Cancer Treatment Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. Cervical Cancer Treatment Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Cervical Cancer Treatment Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Cervical Cancer Treatment Market: Type Movement Analysis, USD Million, 2025 & 2033
• 4.3. Squamous Cell Carcinoma
  • 4.3.1. Squamous Cell Carcinoma Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Adenocarcinoma
  • 4.4.1. Adenocarcinoma Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Adenosquamous Carcinoma
  • 4.5.1. Adenosquamous Carcinoma Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Other Types
  • 4.6.1. Other Types Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Cervical Cancer Treatment Market: Treatment Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Cervical Cancer Treatment Market: Treatment Movement Analysis, USD Million, 2025 & 2033
• 5.3. Radiation Therapy
  • 5.3.1. Radiation Therapy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3.2. External Beam Radiation Therapy (EBRT)
    • 5.3.2.1. External Beam Radiation Therapy (EBRT) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3.3. Brachytherapy
    • 5.3.3.1. Brachytherapy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Chemotherapy
  • 5.4.1. Chemotherapy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.2. Cisplatin
    • 5.4.2.1. Cisplatin Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.3. Carboplatin
    • 5.4.3.1. Carboplatin Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.4. Paclitaxel
    • 5.4.4.1. Paclitaxel Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.5. Other Chemotherapeutic Agents
    • 5.4.5.1. Other Chemotherapeutic Agents Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Targeted Therapy
  • 5.5.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. Bevacizumab (Avastin)
    • 5.5.2.1. Bevacizumab (Avastin) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.3. Other Targeted Therapies
    • 5.5.3.1. Other Targeted Therapies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Immunotherapy
  • 5.6.1. Immunotherapy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6.2. Pembrolizumab (Keytruda)
    • 5.6.2.1. Pembrolizumab (Keytruda) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6.3. Other Immune Checkpoint Inhibitors
    • 5.6.3.1. Other Immune Checkpoint Inhibitors Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Other Therapies
  • 5.7.1. Other Therapies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Cervical Cancer Treatment Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Cervical Cancer Treatment Market: End Use Movement Analysis, USD Million, 2025 & 2033
• 6.3. Hospitals & Clinics
  • 6.3.1. Hospitals & Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Ambulatory Surgery Centers
  • 6.4.1. Ambulatory Surgery Centers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Others
  • 6.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Cervical Cancer Treatment Market: Regional Estimates & Trend Analysis

• 7.1. Cervical Cancer Treatment Market Share, By Region, 2025 & 2033, USD Million
• 7.2. North America
  • 7.2.1. North America Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. U.S. Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.2.3. Canada
    • 7.2.3.1. Canada Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.2.4. Mexico
    • 7.2.4.1. Mexico Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. UK Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Germany
    • 7.3.3.1. Germany Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. France
    • 7.3.4.1. France Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.5. Italy
    • 7.3.5.1. Italy Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.6. Spain
    • 7.3.6.1. Spain Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.7. Denmark
    • 7.3.7.1. Denmark Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.8. Sweden
    • 7.3.8.1. Sweden Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.9. Norway
    • 7.3.9.1. Norway Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. China
    • 7.4.2.1. China Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Japan
    • 7.4.3.1. Japan Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. India
    • 7.4.4.1. India Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.5. South Korea
    • 7.4.5.1. South Korea Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.6. Australia
    • 7.4.6.1. Australia Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.7. Thailand
    • 7.4.7.1. Thailand Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Latin America
  • 7.5.1. Latin America Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Brazil Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Argentina
    • 7.5.3.1. Argentina Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Middle East and Africa
  • 7.6.1. Middle East and Africa Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Saudi Arabia
    • 7.6.2.1. Saudi Arabia Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. UAE
    • 7.6.3.1. UAE Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. South Africa
    • 7.6.4.1. South Africa Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. Kuwait
    • 7.6.5.1. Kuwait Cervical Cancer Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Heat Map Analysis
• 8.4. Company Profiles
  • 8.4.1. Merck & Co., Inc.
    • 8.4.1.1. Participant's Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Recent Developments/ Strategic Initiatives
  • 8.4.2. Bristol-Myers Squibb Company
    • 8.4.2.1. Participant's Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Recent Developments/ Strategic Initiatives
  • 8.4.3. F. Hoffmann-La Roche Ltd
    • 8.4.3.1. Participant's Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Recent Developments/ Strategic Initiatives
  • 8.4.4. Pfizer Inc.
    • 8.4.4.1. Participant's Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Recent Developments/ Strategic Initiatives
  • 8.4.5. Eli Lilly and Company.
    • 8.4.5.1. Participant's Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Recent Developments/ Strategic Initiatives
  • 8.4.6. Novartis AG
    • 8.4.6.1. Participant's Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Recent Developments/ Strategic Initiatives
  • 8.4.7. AstraZeneca
    • 8.4.7.1. Participant's Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Recent Developments/ Strategic Initiatives
  • 8.4.8. GSK plc.
    • 8.4.8.1. Participant's Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Recent Developments/ Strategic Initiatives
  • 8.4.9. AbbVie Inc.
    • 8.4.9.1. Participant's Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Recent Developments/ Strategic Initiatives
  • 8.4.10. Johnson & Johnson Services, Inc.
    • 8.4.10.1. Participant's Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Recent Developments/ Strategic Initiatives